IP Library Granted Patent US 7,820,805
Granted Patent B2
US 7,820,805 · App. 11/861,065 · Granted Oct 26, 2010

Sulfotransferase 2B1 pharmacogenetics

Assignee: Mayo Foundation for Medical Education and Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,820,805
App. No.
11/861,065
Granted
Oct 26, 2010
Kind
B2
Abstract

Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are sulfotransferase allozymes. Methods for determining the sulfonator status of a subject also are described. In addition, methods for predicting the therapeutic efficacy of a compound in a subject are described, as are methods for estimating the dose of a compound to be administered to a subject.

Claims (12)

1. An isolated nucleic acid molecule consisting of: (a) twenty to 100 contiguous nucleotides of SEQ ID NO: 15, wherein said nucleic acid molecule includes at least one nucleotide selected from positions 482, 901, and 1364 of SEQ ID NO: 15, with the proviso that the nucleotide at position 482 is cytosine, the nucleotide at position 901 is adenine, and/or the nucleotide at position 1364 is thymine; or (b) the complement of (a).

2. The isolated nucleic acid molecule of claim 1 , wherein said isolated nucleic acid molecule is 20 to 50 nucleotides in length.

3. A vector comprising the nucleic acid molecule of claim 1 .

4. The vector of claim 3 , wherein said nucleic acid molecule is 20 to 50 nucleotides in length.

5. An article of manufacture comprising a substrate, wherein said substrate comprises the isolated nucleic acid molecule of claim 1 .

6. An isolated nucleic acid molecule consisting of: a) twenty to 100 contiguous nucleotides of SEQ ID NO:15, wherein said nucleic acid molecule includes one or more of nucleotides 482, 901, and 1364 of SEQ ID NO:15, with the proviso that the nucleotide at position 482 is cytosine, the nucleotide at position 901 is adenine, and/or the nucleotide at position 1364 is thymine; or b) the complement of a), and, with respect to a) or b), a label.

7. The isolated nucleic acid molecule of claim 6 , wherein said label is a fluorescent moiety.

8. The isolated nucleic acid molecule of claim 6 , wherein said label is biotin.

9. The isolated nucleic acid of molecule of claim 6 , wherein said isolated nucleic acid molecule is 20 to 50 nucleotides in length.

10. A vector comprising the nucleic acid molecule of claim 6 .

11. The vector of claim 10 , wherein said nucleic acid molecule is 20 to 50 nucleotides in length.

12. An article of manufacture comprising a substrate, wherein said substrate comprises the isolated nucleic acid molecule of claim 6 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2010
From: THOMAE, BIANCA A.; WIEBEN, ERIC D.; WEINSHILBOUM, RICHARD M.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 024570/0616 →
CONFIRMATORY LICENSE Recorded Sep 8, 2008
From: MAYO FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021492/0989 →
Continuity (3)
Division 1070298100 · Nov 6, 2003
Provisional Application 6042442000 · Nov 7, 2002
Related Publication 20080118975A1 · May 22, 2008